Proove's Brian Meshkin Speaks on Personalized Pain Medicine at WVSIPP and AAPM's PAIN 2013 Meeting

IRVINE, Calif. - July 18, 2013 - PRLog -- IRVINE, CA (July 17, 2013) – Proove Biosciences, the leader in personalized pain medication innovation, is excited to announce President and CEO, Brian Meshkin, presented along side leading thought leaders in Pain Management at the Pain, 2013 conference, in Palm Beach, Florida last weekend. The event took place July 11-14, 2013 and was hosted by the West Virginia Society of Interventional Pain Physicians and American Academy of Pain Medicine.

The event united approximately 400 pain practitioners from across the United States. Pain, 2013 brought together clinicians, scientists, researchers, pain medicine specialists, and venture capitalists in an effort to present cutting edge data, information, and science, and provide a forum to interact and discuss evidence based medicine.

On Saturday morning, Brian presented a continuing medical education (CME) program entitled, “Personalized Pain Medicine: The Importance of Pharmacogenetic Testing in Pain Management”, highlighting how advances in technology and science have been helping doctors tailor pain management treatments based on genetic variables. As CEO of Proove Biosciences, he was able to draw on extensive research conducted by Proove, clinical experiences of physicians using Proove testing, and industry guidelines.

On Thursday, Meshkin also had the opportunity to participate in a panel along side David Caraway, MD, the First Executive Vice President of the American Society of Interventional Pain Physicians;  Askomar Buvanendran, MD, a professor at the Rush University Medical Center School of Medicine; and Andrew Thymius, MD, who leads the West Virginia Pain Institute, to examine medical management issues related to a specific case-study during the meeting’s satellite symposium. The panel was led by Lynn Webster, MD, President of the American Academy of Pain Medicine.

“It was great to speak along side these professionals and industry thought leaders,” stated Meshkin. “I am thankful to have had the opportunity to help educate specifically about how genetics can help improve pain management. The enormous interest in this field is a great indication that the promise of personalized medicine is becoming a reality.”

About Proove Biosciences

Proove Biosciences is a Personalized Pain Medicine company that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. Based in Southern California, physicians use Proove testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove Biosciences performs proprietary genetic tests in a CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).